Literature DB >> 11095451

High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus.

H F Escobar-Morreale1, B Roldán, R Barrio, M Alonso, J Sancho, H de la Calle, R García-Robles.   

Abstract

The current recommendation for strict metabolic control of type 1 diabetes mellitus requires the administration of supraphysiological doses of insulin, which might result in insulin-mediated stimulation of androgen synthesis, as occurs in insulin-resistant states. At present, the prevalence of hyperandrogenic disorders in women with type 1 diabetes mellitus is unknown. Eighty-five women with type 1 diabetes mellitus were evaluated for symptoms and signs of hyperandrogenism. In 68 of the patients, several serum androgen and hormone concentrations were measured. The polycystic ovary syndrome (PCOS) was defined by the presence of menstrual dysfunction, together with clinical and/or biochemical evidence of hyperandrogenism, and exclusion of other etiologies. Eighteen healthy women, menstruating regularly, served as controls for the androgenic profiles. Thirty-three patients (38.8%) presented hyperandrogenic disorders (16 had PCOS, and 17 had hirsutism without menstrual dysfunction). Type 1 diabetic patients with PCOS presented increased serum total and free testosterone concentrations, and serum androstenedione levels, but had normal serum sex hormone-binding globulin and dehydroepiandrosterone-sulfate levels. Hirsute type 1 diabetic women without menstrual dysfunction presented normal serum androgen levels. There were no significant differences between hyperandrogenic and nonhyperandrogenic type 1 diabetes mellitus women in clinical variables such as the duration of diabetes, age at diagnosis of diabetes, conventional or intensive insulin therapy, mean daily insulin dosage, or metabolic control. In conclusion, women with type 1 diabetes mellitus have a high prevalence of hyperandrogenic disorders, including PCOS and hirsutism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095451     DOI: 10.1210/jcem.85.11.6931

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Research advances in metabolism 2016.

Authors:  Nikolaos Perakakis; Olivia M Farr; Dario Tuccinardi; Jagriti Upadhyay; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-11-06       Impact factor: 8.694

2.  Ovarian markers and irregular menses among women with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications study.

Authors:  C Kim; R S Miller; B H Braffett; Y Pan; V L Arends; A K Saenger; A Barnie; A V Sarma
Journal:  Clin Endocrinol (Oxf)       Date:  2018-01-26       Impact factor: 3.478

Review 3.  Understanding polycystic ovarian syndrome pathogenesis: an updated of its genetic aspects.

Authors:  A E Calogero; V Calabrò; M Catanuso; R A Condorelli; S La Vignera
Journal:  J Endocrinol Invest       Date:  2011-05-23       Impact factor: 4.256

4.  Assessment of ovarian reserve in patients with type 1 diabetes: a systematic review and meta-analysis.

Authors:  Xiaoling Cai; Linong Ji; Wenjia Yang; Chu Lin; Mengqian Zhang; Fang Lv; Xingyun Zhu; Xueyao Han
Journal:  Endocrine       Date:  2022-05-30       Impact factor: 3.925

5.  Increased aortic stiffness is persistent in type 1 diabetic women: a follow-up study.

Authors:  A R Ahlgren; H Astrand; G Sundkvist; T Länne
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

Review 6.  Glucose intolerance states in women with the polycystic ovary syndrome.

Authors:  R Pasquali; A Gambineri
Journal:  J Endocrinol Invest       Date:  2013-09       Impact factor: 4.256

7.  Type 1 diabetes mellitus and polycystic ovary syndrome.

Authors:  Héctor F Escobar-Morreale; Ane Bayona; Lía Nattero-Chávez; Manuel Luque-Ramírez
Journal:  Nat Rev Endocrinol       Date:  2021-12       Impact factor: 43.330

8.  Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome.

Authors:  Farahnaz Mardanian; Nasrin Heidari
Journal:  J Res Med Sci       Date:  2011-08       Impact factor: 1.852

9.  Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study.

Authors:  A J Swerdlow; S P Laing; Z Qiao; S D Slater; A C Burden; J L Botha; N R Waugh; A D Morris; W Gatling; E A Gale; C C Patterson; H Keen
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

10.  Role of haptoglobin in polycystic ovary syndrome (PCOS), obesity and disorders of glucose tolerance in premenopausal women.

Authors:  Francisco Alvarez-Blasco; Ma Angeles Martínez-García; Manuel Luque-Ramírez; Naiara Parraza; José L San Millán; Héctor F Escobar-Morreale
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.